

17 April 2024

Scancell Holdings plc
("Scancell" or the "Company")

Scancell to present at the Annual Immuno-Oncology Summit Europe

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that it will be presenting at the 8th Immuno-Oncology Summit Europe 2024. The Immuno-Oncology Summit Europe is a world-class event for professionals dedicated to showcasing advancements and innovations in immuno-oncology for breakthrough therapies, and is being held from 23-25 April 2024 in London, UK.

Professor Lindy Durrant, Chief Executive Officer of Scancell, will be speaking in the "Therapeutic Cancer Vaccines" program, where emphasis on clinical studies will be highlighted as part of a broader collection of talks furthering understanding of immunological mechanisms of action, dosing and delivery strategies as well as how such products can be combined with checkpoint inhibitors. Her talk, titled "Clinical Update on the DC Targeting Melanoma Vaccine, SCIB1 and The Modi-1 Vaccine Targeting Citrullination" will take place from 2:45 pm - 3:15 pm BST on Tuesday 23 April 2024.

Professor Lindy Durrant, Chief Executive Officer of Scancell, said: "I am pleased to be invited to share this exciting data on SCIB1, Scancell's 'off the shelf' ImmunoBody[®] cancer vaccine, which has demonstrated positive efficacy data from the Phase 2 SCOPE trial for advanced unresectable melanoma. I am also looking forward to presenting early data from patients receiving Modi-1 as a monotherapy in range of hard-to-treat solid tumours, which has shown good T cell responses, safety and tolerability. Following on from AACR, there has been significant interest in the clinical development of therapeutic cancer vaccines, and I am excited to demonstrate the progress Scancell has made in this class of immunotherapies."

If you would like to arrange a meeting with management, please contact commercial.enquiries@scancell.co.uk.

-ENDS-

For further information, please contact:

Scancell Holdings plc +44 (0) 20 3709 5700

Professor Lindy Durrant, CEO

Dr Jean-Michel Cosséry, Non-Executive Chairman

Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) +44 (0) 20 7710 7600

Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)

Nick Adams/Nick Harland (Corporate Broking)

WG Partners LLP (Joint Broker) +44 (0) 20 3705 9330

David Wilson/Claes Spang/Sathesh Nadarajah/Erlend Sternby

Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500

Freddy Crossley/Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

ICB Scancell

+44 (0) 20 3709 5700

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope[®] and ImmunoBody[®] for vaccines and GlyMab[®] and AvidiMab[®] for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope[®] and ImmunoBody[®]) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab[®]) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab[®]).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCIFMPTMTABBMI